Keytruda, an immuno-cancer drug, has been leading the domestic pharmaceutical market for the second consecutive year. K-CAB continued to soar among new drugs from multinational pharmaceutical companies.

According to IQVIA, a pharmaceutical research institute on the 26th, Keytruda of MSD Korea recorded 145.5 billion won in sales in the third quarter of this year, the largest number of all medicines. It recorded a high growth rate of 27.8% year-on-year, widening the gap with the second-ranked Lipitor by more than 30 billion won. Until the first half of the year, the gap between Keytruda and Lipitor was 19.9 billion won. Keytruda ranked first among all medicines for the first time with sales of 155.7 billion